Evidence map›Paper›PMID 35755946›Full record

ArticleMolecular therapy. Methods & clinical development2022

Thermostable H1 hemagglutinin stem with M2e epitopes provides broad cross-protection against group1 and 2 influenza A viruses.

Jeeva Subbbiah, Judy Oh, Ki-Hye Kim, Chong Hyun Shin, Bo Ryoung Park, Noopur Bhatnagar, Yu-Jin Jung, Youri Lee, Bao-Zhong Wang, Baik-Lin Seong and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Jeeva SubbbiahCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Avenue, PSC 718 P.O. Box 5035, Atlanta, GA 30303, USA.
Judy OhCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Avenue, PSC 718 P.O. Box 5035, Atlanta, GA 30303, USA.
Ki-Hye KimCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Avenue, PSC 718 P.O. Box 5035, Atlanta, GA 30303, USA.
Chong Hyun ShinCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Avenue, PSC 718 P.O. Box 5035, Atlanta, GA 30303, USA.
Bo Ryoung ParkCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Avenue, PSC 718 P.O. Box 5035, Atlanta, GA 30303, USA.
Noopur BhatnagarCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Avenue, PSC 718 P.O. Box 5035, Atlanta, GA 30303, USA.
Yu-Jin JungCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Avenue, PSC 718 P.O. Box 5035, Atlanta, GA 30303, USA.
Youri LeeCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Avenue, PSC 718 P.O. Box 5035, Atlanta, GA 30303, USA.
Bao-Zhong WangCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Avenue, PSC 718 P.O. Box 5035, Atlanta, GA 30303, USA.
Baik-Lin SeongDepartment of Microbiology, College of Medicine, Yonsei University, Seoul 03722, Republic of Korea.
Sang-Moo KangCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 100 Piedmont Avenue, PSC 718 P.O. Box 5035, Atlanta, GA 30303, USA.
Georgia State University · USYonsei University · KR

Funding

Influenza vaccines inducing broadly cross protective immunityR01AI093772 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2011 to 2020
$4.2M
Seasonal and universal Vaccination in aged populations with pre-existing immunityR01AI154656 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2021 to 2025
$2.7M
Universal epitopes-based recombinant influenza vaccinesR21AI147042 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2020 to 2021
$428k
NIAID NIH HHS R01 AI093772NIAID NIH HHS R01 AI154656NIAID NIH HHS R21 AI147042
6 · The paper itself

Abstract

Hemagglutinin (HA) stem-based vaccines have limitations in providing broad and effective protection against cross-group influenza viruses, despite being a promising universal vaccine target. To overcome the limited cross-protection and low efficacy by HA stem vaccination, we genetically engineered a chimeric conjugate of thermostable H1 HA stem and highly conserved M2e repeat (M2e-H1stem), which was expressed at high yields in

Indexed as

chimeric M2e-H1stem proteincross-group protectioninfluenza A virusM2e

Identifiers

PMID35755946
PMCPMC9198381
OpenAlexW4281969122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.